Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Free Cash Flow (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Free Cash Flow data on record, last reported at -$4.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 71.42% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached -$17.6 million, up 71.08%, while the annual FY2025 figure was -$17.6 million, 71.08% up from the prior year.
  • Free Cash Flow reached -$4.6 million in Q4 2025 per VRCA's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $9.7 million in Q3 2025 and bottomed at -$19.9 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$8.2 million, with a median of -$8.8 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 951.03% in 2023, then skyrocketed 212.71% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$8.9 million in 2021, then surged by 43.82% to -$5.0 million in 2022, then plummeted by 193.51% to -$14.7 million in 2023, then fell by 9.03% to -$16.1 million in 2024, then surged by 71.42% to -$4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$4.6 million in Q4 2025, $9.7 million in Q3 2025, and -$10.0 million in Q2 2025.